AzTrials
AzTrials

BioequivalencePhase 1NCT05663398

Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers

A Phase 1 study testing Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate) and Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate) in people with Bioequivalence and Healthy Subjects, run by Darnitsa Pharmaceutical Company at 1 site in Jordan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a comparative bioavailability study performed to assess bioequivalence between Test medicinal product (Darfen 400, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by PrJSC "Pharmaceutical firm "Darnitsa" [Ukraine]) and Reference medicinal product (marketed medicinal… Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Bioequivalence, Healthy Subjects
What is being tested?
Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate) and Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 siteJordan
Study dates
17 May 2022to 31 May 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • The subject is Caucasian \& aged between eighteen to fifty years (18 - 50), both inclusive.
  • The subject is within the limits for his height \& weight as defined by the body mass index range (18.5 - 30.0 Kg/m2).
  • The subject is willing to undergo the necessary pre- \& post- medical examinations set by this study.
  • The results of medical history, physical examination, vital signs \& conducted medical laboratory tests are normal as determined by the clinical investigator.
  • The subject tested negative for Hepatitis B (HBsAg), Hepatitis C (HCVAb), human immunodeficiency virus (HIV Ab).
  • There is no evidence of psychiatric disorder, antagonistic personality, and poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
Show all 10Show fewer
  • The subject is able to understand and willing to sign the informed consent form.
  • For female subjects: a negative pregnancy test must be confirmed, and if sexually active, at least 4 weeks of highly effective contraceptive method must be used prior to IMP administration and throughout the study progress until last visit; highly effective methods comprise hormonal contraceptives, intrauterine devices IUDs, sexual abstinence or vasectomized partner (success of vasectomy was medically proven). For subjects using a hormonal contraceptive method, a barrier form of contraception should be combined with the hormonal contraception.
  • The subject kidney and liver (AST \& ALT enzymes) functions tests are within normal range.
  • The subject has normal gastrointestinal, respiratory \& cardiovascular systems.

Who cannot join

  • Subject is a smoker or an ex-smoker with a non-smoking history of less than 6 months.
  • The subject has suffered an acute illness one week before dosing.
  • The subject has a history of or concurrent abuse of alcohol.
  • The subject has a history of or concurrent abuse of illicit drugs.
  • The subject has a history of hypersensitivity and/or contraindications to the study drug and any related compounds.
  • The subject has been hospitalized within three months before the study or during the study.
Show all 16Show fewer
  • The subject is on special diet (for example subject is vegetarian).
  • The subject has consumed caffeine or xanthine containing beverages or foodstuffs within two days before dosing and until 24 hours after dosing in all study periods.
  • The subject has taken a prescription medication within two weeks or even an over-the-counter product (OTC) within one week before dosing in each study period and any time during the study, unless otherwise judged acceptable by the clinical investigator.
  • The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before first dosing and any time during the study.
  • The subject has been participating in any clinical study (e.g., pharmacokinetics, bioavailability and bioequivalence studies) within the last 80 days prior to the present study.
  • The subject has donated blood within 80 days before first dosing.
  • The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinal, immunological, dermatological, neurological, musculoskeletal or psychiatric diseases.
  • The subject has consumed drugs that may affect pharmacological or pharmacokinetic properties of Ibuprofen (for example: aspirin, celecoxib, ciprofloxacin, diclofenac, etodolac, fish oil, heparin, ketorolac, ketoprofen, naproxen, rivaroxaban, vitamin B12, vitamin C and vitamin D3) two weeks before dosing, during the study and two weeks after dosing.
  • Pregnant; with positive serum pregnancy test or breast-feeding female subjects.
  • The subject has a history of, or active, peptic ulceration, gastritis, esophagitis, gastrointestinal bleeding or perforation.

Trial locations and contacts

1 site in 1 country.

Jordan1 site

  • ACDIMA Center for Bioequivalence and Pharmaceutical Studies

    Amman, 11190

Other trials in Jordan

About this study

Official title: Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Darfen 400, 400 mg Ibuprofen Coated Tablets (512 mg Ibuprofen Sodium Dihydrate) Versus Nurofen® Forte Express, 400 mg Ibuprofen Coated Tablets (512 mg Ibuprofen Sodium Dihydrate) in Healthy Adult Male and Female Subjects Under Fasting Conditions

This study is a comparative bioavailability study performed to assess bioequivalence between Test medicinal product (Darfen 400, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by PrJSC "Pharmaceutical firm "Darnitsa" [Ukraine]) and Reference medicinal product (marketed medicinal product Nurofen® Forte Express, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by Reckitt Benckiser [Poland] S.A.) in healthy volunteers.

Being tested
Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate), Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Keywords
healthy subjects, ibuprofen, pharmacokinetics, bioequivalence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)Drug

    Oral, a nonsteroidal anti-inflammatory drug

  • Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)Drug

    Oral, a nonsteroidal anti-inflammatory drug

Study groups in NCT05663398
Study groupRoleWhat they receive
Darfen 400ExperimentalA single oral dose of the test product Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Receives: Drug: Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Nurofen® Forte ExpressActive comparatorA single oral dose of the reference product Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Receives: Drug: Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum plasma concentration (Cmax)

    The Cmax value is based on the ibuprofen plasma concentration.

    Measured: Blood sampling for pharmacokinetic analysis covered up to 24 hours post-dose

  2. Area under the concentration-time curve from time zero to the last quantifiable concentration (t)

    The AUC0-t is the area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (t) and is based on the ibuprofen plasma concentration.

    Measured: Blood sampling for pharmacokinetic analysis covered up to 24 hours post-dose

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2022
  2. Study start17 May 2022
  3. Primary completion31 May 2022
  4. Study completion31 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Model description
Two-period, two-sequence, two-way crossover single dose study
Masking
None (open label)
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05663398
Sponsor's protocol ID
IBF02-E
Status last verified
Dec 2022
First submitted
15 Dec 2022
Last updated
23 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate) and Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate) in people with Bioequivalence and Healthy Subjects, run by Darnitsa Pharmaceutical Company at 1 site in Jordan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum plasma concentration (Cmax) (time frame: Blood sampling for pharmacokinetic analysis covered up to 24 hours post-dose). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05663398.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in